Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

New research from University of Iowa dispels the belief that pharmaceutical mergers lead to higher drug prices, showing a decrease in prices for generic drugs.

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...

The GCC, to be known as the Lilly Capability Centre India (LCCI), will be the company’s second centre in the country, ...

Forty submissions, weeks of polls and several thousand votes from Herald-Leader subscribers have finally brought us to this ...

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

A $2.48 million grant from the Lilly Endowment is expected to help Baylor University expand its Black Gospel Archive and ...

Eli Lilly should become a much bigger money machine with multiple growth drivers in its product lineup and a promising ...